ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
Maternal Influenza Vaccine Reduces the Risk of Respiratory Syncytial Virus and Related Respiratory Hospitalizations in Early Infancy: An Epidemiological Study.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundWe examined the impact of maternal inactivated influenza vaccine (IIV) on respiratory syncytial virus (RSV) hospitalizations in Western Australian infants aged ≤6 months.
methodsWe conducted a population-based cohort study of births from April 2012 to December 2020 using linked, longitudinal data on births, deaths, perinatal data, hospitalizations, antenatal immunization records, and respiratory pathogen laboratory testing, with follow-up to 31 December 2021. We performed Cox proportional hazards models with inverse probability treatment weighting. Mother's receipt of IIV was the exposure against the primary outcome, RSV-confirmed hospitalization in infants, adjusting for sociodemographic and perinatal factors and stratifying by vaccination trimester. Secondary outcomes included International Classification of Diseases-coded pneumonia, bronchiolitis, and all-cause acute respiratory infection hospitalizations.
resultsThe cohort comprised 288 059 infants. Overall, 87 277 mothers (30.3%) received a maternal IIV. There were 2707 RSV-confirmed hospitalizations in 2702 infants aged ≤6 months, the majority (69.7%) occurring in maternally unvaccinated infants. Exposure to maternal IIV was associated with an overall nonsignificant 10.0% reduction in RSV hospitalizations (weighted adjusted hazard ratio [aHR], 0.90 [95% confidence interval {CI}, .80-1.01]) compared with maternally unvaccinated infants. However, by trimester, maternal IIV was most effective when administered in first (weighted aHR, 0.65 [95% CI, .50-.85]) or second (weighted aHR, 0.75 [95% CI, .62-.90]) trimesters. Maternal IIV was associated with a 35.0% and 25.0% reduced risk against RSV hospitalizations when administered in the first or second trimester, respectively. Similar findings were observed for secondary outcomes.
conclusionsNonspecific effects should be included in the full public health evaluation of maternal IIV. These findings are important for policymakers and community to improve immunization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.